Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 500

1.

Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial.

Praga M, Andrade CF, Luño J, Arias M, Poveda R, Mora J, Prat MV, Rivera F, Galceran JM, Ara JM, Aguirre R, Bernis C, Marín R, Campistol JM.

Nephrol Dial Transplant. 2003 Sep;18(9):1806-13.

2.

Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.

Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T; Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.

Clin Exp Nephrol. 2003 Sep;7(3):221-30.

PMID:
14586719
3.

Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.

Park HC, Xu ZG, Choi S, Goo YS, Kang SW, Choi KH, Ha SK, Lee HY, Han DS.

Nephrol Dial Transplant. 2003 Jun;18(6):1115-21.

4.

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.

PMID:
14586737
5.

Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients.

Iñigo P, Campistol JM, Lario S, Piera C, Campos B, Bescós M, Oppenheimer F, Rivera F.

J Am Soc Nephrol. 2001 Apr;12(4):822-7.

6.

The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.

Nephrol Dial Transplant. 2000 Apr;15(4):487-97.

7.

Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.

Renke M, Tylicki L, Rutkowski P, Wojnarowski K, Lysiak-Szydlowska W, Rutkowski B.

Scand J Urol Nephrol. 2005;39(6):511-7.

PMID:
16303729
8.

[Pharmacogenetics of angiotensin system in non diabetic nephropathy].

Coto E, Marín R, Alvarez V, Praga M, Fernández Andrade C, Arias M, Poveda R, Vallés M, Galcerán JM, Luño J, Rivera F, Campistol JM.

Nefrologia. 2005;25(4):381-6. Spanish.

9.

Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial.

Boero R, Rollino C, Massara C, Vagelli G, Gonella M, Berto IM, Bajardi P, Perosa P, Malcangi U, Giorgi MP, Ghezzi PM, Borzumati M, Baroni AM, Cogno C, Triolo G, Angelini D, Antonelli A, Quarello F.

J Nephrol. 2001 Jan-Feb;14(1):15-8.

PMID:
11281338
10.

Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.

Agarwal R, Siva S, Dunn SR, Sharma K.

Am J Kidney Dis. 2002 Mar;39(3):486-92.

PMID:
11877567
11.

[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.

Presse Med. 2002 Nov 9;31(36):1714-20. Review. French.

PMID:
12467154
12.

Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients.

el-Agroudy AE, Hassan NA, Foda MA, Ismail AM, el-Sawy EA, Mousa O, Ghoneim MA.

Am J Nephrol. 2003 Sep-Oct;23(5):300-6. Epub 2003 Aug 6.

PMID:
12904684
13.

Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy.

Holdaas H, Hartmann A, Berg KJ, Lund K, Fauchald P.

Nephrol Dial Transplant. 1998 Dec;13(12):3096-102.

14.

Urinary TGF-beta1 as an indicator of antiproteinuric response to angiotensin II receptor blocker in proteinuric renal diseases.

Park HC, Choi HY, Kim BS, An HR, Lee JS, Ha SK, Han DS.

Biomed Pharmacother. 2009 Nov;63(9):672-8. doi: 10.1016/j.biopha.2009.02.002. Epub 2009 Feb 28.

PMID:
19278811
15.
17.

Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure.

Mora-Macía J, Cases A, Calero F, Barceló P.

Nephrol Dial Transplant. 2001;16 Suppl 1:82-4.

18.

The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.

Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z; Amlodipine Versus Enalapril in Renal failure (AVER) Study Group.

Clin Ther. 2008 Mar;30(3):482-98. doi: 10.1016/j.clinthera.2008.03.006.

PMID:
18405787
19.

Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.

Erman A, Veksler S, Gafter U, Boner G, Wittenberg C, van Dijk DJ.

J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):146-51.

PMID:
15526251
20.

Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study.

Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchii Y, Uchida S, Kuwahara M, Yamazaki T; Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.

Hypertens Res. 2004 Jan;27(1):21-30.

Items per page

Supplemental Content

Write to the Help Desk